Revumenib in Patients With Myelofibrosis
Revumenib in Patients With Myelofibrosis
Not yet recruiting · NCT07734077 · Registry updated 2026-07-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT07734077 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| John Mascarenhas | 3 |
| National Cancer Institute (NCI) | 3015 |
| Syndax Pharmaceuticals | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at the Mount Sinai Hospital | New York | United States | 1 |